뒤로
DMK Pharmaceuticals Corp(DMKPQ) 가격
DMKPQ 주가 차트
DMKPQ 수입
DMK Pharmaceuticals Corp
$0
0%
$0
종가: Feb 11, 16:00:00 GMT-5
$0
0%
$0
애프터마켓: Feb 11, 20:00:00 GMT-5
최신 수익 결과: Q3 '23
보고됨: 2023-11-14
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
DMKPQ의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
DMK Pharmaceuticals Corp DMKPQ의 지난 분기 매출 실적은 어땠나요?
DMK Pharmaceuticals Corp의 매출 추정치는 얼마인가요?
DMK Pharmaceuticals Corp의 수익 품질 점수는 얼마인가요?
DMK Pharmaceuticals Corp는 언제 수익을 보고하나요?
DMK Pharmaceuticals Corp의 예상 수익은 얼마인가요?
DMK Pharmaceuticals Corp은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0001
시가
$0.0001
일일 범위
$0.0001 - $0.0001
52주 범위
$0 - $0.001
거래량
1
평균 거래량
7.7K
EPS(TTM)
-9.19
배당수익률
--
시가총액
$1.0K
DMKPQ란 무엇인가요?
DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. The company is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.